Tesofensine
Small-molecule triple monoamine reuptake inhibitor (not a peptide)
Tesofensine is an orally active small-molecule triple monoamine reuptake inhibitor first trialed for neurodegenerative disease and later repurposed for obesity. It is not a peptide. It remains investigational and is not FDA-approved, though it produced notable weight loss in Phase 2 obesity trials.
Mechanism under study
Inhibits presynaptic reuptake of noradrenaline, dopamine, and serotonin, increasing their synaptic availability to enhance satiety and, to a lesser degree, energy expenditure.
Research-reported dosing
Investigational and not FDA-approved. Phase 2 obesity trials reported roughly 0.25-1.0 mg orally once daily for up to 24 weeks, with the 0.5 mg dose most studied. Reported, not recommended.
Not a reconstituted injectable. Tesofensine is an orally active small molecule administered as a tablet, capsule, or oral solution; bacteriostatic water reconstitution does not apply.
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Tesofensine FAQ
What is Tesofensine?
Tesofensine is an orally active small-molecule triple monoamine reuptake inhibitor first trialed for neurodegenerative disease and later repurposed for obesity. It is not a peptide. It remains investigational and is not FDA-approved, though it produced notable weight loss in Phase 2 obesity trials.
What is the half-life of Tesofensine?
Long, reported near 9 days (roughly 220 hours), which supports once-daily oral dosing.
What is the research-reported dosing for Tesofensine?
Investigational and not FDA-approved. Phase 2 obesity trials reported roughly 0.25-1.0 mg orally once daily for up to 24 weeks, with the 0.5 mg dose most studied. Reported, not recommended.
How is Tesofensine reconstituted?
Not a reconstituted injectable. Tesofensine is an orally active small molecule administered as a tablet, capsule, or oral solution; bacteriostatic water reconstitution does not apply.
Is Tesofensine FDA-approved?
Tesofensine has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.
References
Related peptides
Semaglutide
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist, FDA-approved for type-2 diabetes and chronic weight management under brand names Ozempic, Wegovy, and Rybelsus. One of the most-studied incretin peptides.
Tirzepatide
Dual GIP / GLP-1 receptor agonist
A dual GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (weight management). Trials reported notably large reductions in body weight.
SLU-PP-332
Small-molecule ERR agonist (not a peptide)
SLU-PP-332 is a small-molecule agonist of the estrogen-related receptors investigated as an exercise-mimetic candidate that increases oxidative metabolism and endurance in rodents. Despite being frequently grouped with research peptides, it is not a peptide. Evidence is preclinical with no human data, and it is not approved.